Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) mediates B cell receptor (BCR) and Fc receptor (FcR) signalling in several hematopoietic cell lineages, including B cells, macrophages and neutrophils. The BTK inhibitor evobrutinib silences B cells and prevents innate immune activation via FcR and is efficacious in preclinical models for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Macrophages can have pro-inflammatory and anti-inflammatory properties and thus they play a crucial role in exacerbation versus control of autoimmune disease. BTK function has been implied downstream of certain cytokine receptors that control macrophage differentiation. The aim of this preclinical study was to investigate the effect of BTK inhibition on the differentiation and activation of monocytes and macrophages.
Monocytes were isolated from the peripheral blood of healthy volunteers. BTK activation was analyzed by Western blot following a 30-minute BTK inhibitor treatment and a subsequent granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulation time course. Survival of GM-CSF differentiated M1 cells was analyzed by flow cytometry following AnnexinV/PI staining. Expression levels of IL-1ß and IL-10 were determined by qPCR following 48 hours of GM-CSF stimulation and BTK inhibitor treatment. TNF-α levels in cell culture supernatants were measured by ELISA following overnight LPS stimulation and BTK inhibitor treatment. The uptake of apoptotic cells by M2 macrophages was analyzed by flow cytometry.
BTK was activated downstream of the GM-CSF receptor. In line with this finding, in vitro GM-CSF differentiated M1 macrophages underwent apoptosis upon BTK inhibition using evobrutinib. Monocytes treated with GM-CSF in the presence of BTK inhibitor secreted less TNF-α and expressed less IL-1ß, and the expression of anti-inflammatory genes, such as IL-10, was upregulated. Furthermore, treatment with BTK inhibitor increased the rate of phagocytosis by anti-inflammatory M2 macrophages in vitro.
Our findings show that BTK inhibition hinders M1 macrophage differentiation and skews monocytes towards an anti-inflammatory M2 phenotype, while enhancing apoptotic cell uptake by M2 cells. Therefore, BTK inhibition could have additional benefits in the treatment of autoimmune diseases such as RA and SLE, by targeting both B cells and myeloid cells simultaneously.
To cite this abstract in AMA style:Beguem Alankus Y, Grenningloh R, Haselmayer P, Bender A, Bruttger J. Inhibition of Bruton’s Tyrosine Kinase (BTK) Prevents Inflammatory Macrophage Differentiation: A Potential Role in RA and SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/inhibition-of-brutons-tyrosine-kinase-btk-prevents-inflammatory-macrophage-differentiation-a-potential-role-in-ra-and-sle/. Accessed April 21, 2019.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-brutons-tyrosine-kinase-btk-prevents-inflammatory-macrophage-differentiation-a-potential-role-in-ra-and-sle/